Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Source :: GlobeNewswire. March 7, 2023
Publication Year :: 2023
Abstract: MINNEAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]

Subjects :: Gemcitabine
Sulindac
Metastasis -- Care and treatment
Paclitaxel
Pancreatic cancer -- Care and treatment
Banking, finance and accounting industries
Business

Tools